tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2026 Dec;22(1):2662118.
doi: 10.1080/21645515.2026.2662118. Epub 2026 May 19.
Safety of COVID-19 mRNA-1273 booster doses in Asian populations: A literature review of post-marketing observational studies
Chris Clarke[SUP] 1 [/SUP], Daina Esposito[SUP] 2 [/SUP], Veronica Urdaneta[SUP] 2 [/SUP], Piyali Mukherjee[SUP] 3 [/SUP], Amanda K Buttery[SUP] 1 [/SUP]
Affiliations
Real-world data on the safety of COVID-19 booster doses in Asian populations are needed to inform national immunization programs. The safety profile of mRNA-1273 (Moderna, Inc.) was evaluated using post-marketing observational data. PubMed and EMBASE were searched on June 30, 2025, for studies meeting the following predefined criteria: observational design, adverse events (AEs), mRNA-1273 boosters (dose 3+), and population data from the South-East Asia and Western-Pacific regions. Data on study characteristics, and AE incidence and severity, were extracted. Of 886 records screened, 27 studies from eight countries (Japan, the Republic of Korea, Australia, Taiwan, Indonesia, Thailand, the Philippines, and Singapore) met the inclusion criteria. Across studies, mRNA-1273 boosters were well tolerated, with severe AEs occurring at low frequency. Based on the included observational studies, these findings support the favorable safety profile of mRNA-1273 boosters in Asian populations. Long-term safety monitoring is needed to guide public-health responses to evolving SARS-CoV-2 variants.
Keywords: COVID-19; SARS-CoV-2; adverse event; booster; literature review; mRNA; mRNA-1273; safety; vaccine.
. 2026 Dec;22(1):2662118.
doi: 10.1080/21645515.2026.2662118. Epub 2026 May 19.
Safety of COVID-19 mRNA-1273 booster doses in Asian populations: A literature review of post-marketing observational studies
Chris Clarke[SUP] 1 [/SUP], Daina Esposito[SUP] 2 [/SUP], Veronica Urdaneta[SUP] 2 [/SUP], Piyali Mukherjee[SUP] 3 [/SUP], Amanda K Buttery[SUP] 1 [/SUP]
Affiliations
- PMID: 42154963
- DOI: 10.1080/21645515.2026.2662118
Real-world data on the safety of COVID-19 booster doses in Asian populations are needed to inform national immunization programs. The safety profile of mRNA-1273 (Moderna, Inc.) was evaluated using post-marketing observational data. PubMed and EMBASE were searched on June 30, 2025, for studies meeting the following predefined criteria: observational design, adverse events (AEs), mRNA-1273 boosters (dose 3+), and population data from the South-East Asia and Western-Pacific regions. Data on study characteristics, and AE incidence and severity, were extracted. Of 886 records screened, 27 studies from eight countries (Japan, the Republic of Korea, Australia, Taiwan, Indonesia, Thailand, the Philippines, and Singapore) met the inclusion criteria. Across studies, mRNA-1273 boosters were well tolerated, with severe AEs occurring at low frequency. Based on the included observational studies, these findings support the favorable safety profile of mRNA-1273 boosters in Asian populations. Long-term safety monitoring is needed to guide public-health responses to evolving SARS-CoV-2 variants.
Keywords: COVID-19; SARS-CoV-2; adverse event; booster; literature review; mRNA; mRNA-1273; safety; vaccine.